Effect of Resveratrol on Fatty Acid Compositons and Lipofilic Vitamins of Fructose Induced Nonalcholic Fatty Liver

Mehmet Guvenc[1,*], Ayşe Nilay Guvenc[3], Ökkeş Yılmaz[2] and Mehmet Tuzcu[2]

[1]*Department of Biology, Faculty of Sciences, Adıyaman University, TR-02100 Adıyaman, Turkey*
[2]*Department of Biology, Faculty of Science, Firat Univerity, TR-23119 Elazig, Turkey*
[3]*Vocational School of Health Services, Adıyaman University, Adıyaman, Turkey*

A B S T R A C T

İn this study, the effect of resveratrol on the liver of rats induced by fructose was investigated. Adult male Winstar rats were randomly divided into four groups; control, resveratrol, fructose, and resveratrol plus fructose. Resveratrol was administered 30 mg/kg intraperitoneally. Fructose (10% w/v) was administered with drinking water for 56 days every alternate day. Fructose administration increased the hepatic omega-6/omega-3 and 16:1 n7 / 16:0 ratios ($p<0.001$, $p<0.001$), but decreased the retinol and alfa tocoferol levels ($p<0.01$) compared with control group. Resveratrol administration to fructose treated rats decreased the retinol and cholesterol levels ($p<0.01$, $p<0.05$), and increased alfa tocoferol and vitamin d_3 levels ($p<0.01$) in the liver. Our results suggest that resveratrol act as a bioregulator for some biochemical parameters in fructose induced non-alcoholic fatty liver.

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease that affects 20–30% of adults and 10% of children especially in industrialized countries, the prevalence of which is increasing all over the world. Prevalence of NAFLD is 15–40% in Western countries and 9–40% in the Asian population. NAFLD encompasses a spectrum of liver disease that ranges from steatosis to its progressive subtype nonalcoholic steatohepatitis (NASH), which can progress to hepatocellular carcinoma and liver cirrhosis. NAFLD is linked to insulin resistance, hypertriglyceridemia (Tessari *et al*., 2009) and it is considered to be the hepatic manifestation of the metabolic syndrome which includes obesity, hypertension and dyslipidemia (McCarthy and Rinella, 2012; Bernal *et al*., 2013).

Lipid peroxidation, inflammation and chronic oxidative stress is associated with pathogenesis of NASH. Higher free radical activity with overproduction of free radicals overcomes the antioxidant defenses and depleted antioxidants levels via lipid peroxidation which prediposes the liver to be more susceptible to oxidative damage (Rhee *et al*., 2013; Browning and Horton, 2004; Oliveira *et al*., 2002; Yu *et al*., 2010; Serviddio *et al*., 2013).

Herbal medicines and their derivatives are widely used for the treatment of NAFLD (Mao *et al*., 2012; Yang *et al*., 2011; Dong *et al*., 2012). Natural products such as *Lycii fructus (*wolfberry derivated), *Silybum marianum* derivatives (silymarin and silibinin), curcumin, garlic**,** green tea and grape derivated resveratrol are used in experimental liver injuries (Xiao *et al*., 2012, 2013; Kang *et al*., 2011; Masterjohn and Bruno, 2012). Several mechanism as such as antioxidant properties, insülin sensitivity, antidyslipidemic properties of herbal have beneficial effects on NAFLD (Mao *et al*., 2012; Yang *et al*., 2011; Dong *et al*., 2012; Kang *et al*., 2011; Masterjohn and Bruno, 2012). Resveratrol is a naturally ocurring polyphenol compound belonging to the stilbene class of aromatic phytochemicals, found in the skin of grapes, berries and peanuts and *Polygonum cuspidatum* roots (Kim *et al*., 2011). It is found in nature as cis and trans isomers. Trans forms are biologically active and most abundant. They are produced by plants as a defensive response to microbial injury, fungal infection, or abiotic (*i.e.* environmental) stress. They have beneficial effects on hepatic, neurological, diabetes, cancer, cardiovascular diseases. They also improve insulin sensitivity and lower body and liver weight and also alleviates steatosis (Xiao *et al*., 2013; Shang *et al*., 2008; Gomez-Zorita *et al*., 2012; Xin *et al*., 2013).

Omega-3 PUFAs are unable to be synthesised de novo and essential in human diet (Zivkovic *et al*., 2007). According to Toshimitsu *et al.* (2007) and Cortez-Pinto *et*

al., (2006) individuals with NAFLD have lower dietary intake of omega-3 fatty acids and their hepatic long chain fatty acid composition altered. Levels of n−3 PUFA (polyunsaturated fatty acids) decreased and n_6/n_3 ratio is increased. This alterations in the fatty acid compositon of individuals with NAFLD is associated with a pro-inflammatory state and increased lipogenesis leading to steatosis (Parker *et al.*, 2012; Serviddio *et al.*, 2013).

n-3 LC-PUFAs decrease liver steatosis by decreasing the expression of delta 9 desaturase enzymes, lipogenesis and stimulating fatty acid oxidation in the liver (Parker *et al.*, 2012).

We aimed to study the effect of resveratrol on some lipophilic vitamins and fatty acids levels of fructose induced non-alcholic fatty liver.

MATERIALS AND METHODS

Animals

A total of 28 male Wistar rats (n=28, 8 weeks), supplied by Elazıg Animal Diseases Research Center of the Agricultural Ministry of Turkey, were used in this study. Rats were housed in cages where they had ad libitum rat chow and water in an air-condition room with 12-h light/12-h dark cycle. Animals were randomly divided into four groups: The first group was (i) Negative control (n = 6) nutriet with standard diet without resveratrol and fructose, (ii) second group(ii) positive control (n=6) nutrient with standard diet plus resveratrol without fructose (30 mg/kg live weight daily i.p.); (iii) Third group: nutrient with standard diet plus fructose (10% w/v drink water); (iv) Fructose plus resveratrol group; nutriet with fructose and resveratrol. Fructose was given to animal with drinking water by a ratio of 10% w/v. Resveratrol is injected to animal 30 mg/kg intraperitoneally. These treatments were continued for seven weeks after which, each experimental rat was anesthetized with ether. Liver tissue samples were collected and stored in -85°C prior to biochemical analyses. Liver fatty acid levels were determined using Gas chromatography, the vitamin levels in liver were determined by HPLC.

Lipid extraction

The lipid of liver tissue samples were extracted by the method of Hara and Radin (1978). Tissue samples were homogenized with the mixture of hexane: isopropanol (3:2 v/v) in the homogenizer. Aliquots of the lipid extract were esterified with 2% H_2SO_4-methanol (Christie, 1992) and the fatty acid composition was determined by gas chromatography (GC).

Fatty acid composition analayses

Fatty acid methyl ester forms (FAME) were extracted

with n-hexane. Gas chromatography analysis was employed GC-17A instrument with FID and AOC-20i Autoinjector and Autosampler from Shimadzu (Kyota, Japan). FAMEs were separated by fused silica capiller column, 25 m length and 0.25 mm diameter, Permabond (Machhery–Nagel, Germay). Column temperature was programmed between 120–220C, 5°C/min and the final temperature was held for 15 min. Injector and FID temperatures were 240 and 280°C, respectively. Nitrogen was used as carrier gas under head pressure of 50 kPa (corresponding to 1.2 ml/min, 43 cm/s column flow rate). Identification of the individual methyl esters was performed by frequent comparison with authentic external standard mixtures analyzed under the same conditions. Class GC 10 software version 2.01 assisted in working of the data.

Determination of lipid soluble vitamins

Liver tissue samples (500mg) were homogenized in 5 ml acetonitrile/methanol/isopropyl alcohol (2:1:1 v/v/v)-containing tubes and the samples were vortexed for 30 s and centrifuged at 6000×g for 10 min at 4°C. Supernatants were transferred to autosampler vials of the HPLC instrument (Shimadzu, Kyoto Japan). For lipophylic vitamins, the mixture of acetonitrile/methanol (75/25 %) was used as the mobile phase and the elution was performed at a flow-rate of 1 ml/min. The temperature of analytical column was kept at 30°C. (Bragagnolo and Rodriguez-Amaya, 2003). Supelcosil™ LC 18 DB column (250 × 4.6 mm, 5 μm; Sigma, USA) was used as the HPLC column and detection were performed at 320 nm for retinol (vitamin A) and retinol acetate, and 215 nm for δ-tocopherol, vitamins D2, D3 and K1, α-tocopherol, α-tocopherol acetate (Katsanidis and Addis, 1999). Identification of the individual vitamins was performed by frequent comparison with authentic external standard mixtures analyzed under the same conditions. Quantification was carried out by external standardization using Class VP software. The results of the analysis were expressed as μg/g wet cell pellet (Katsanidis and Addis, 1999).

Cholesterol analysis

Liver tissue samples (500 mg) were extracted in 5 ml acetonitrile/isopropyl alcohol (70:30 v/v) containing tubes and the mixture were vortexed for 30 s and centrifuged at 6000×g for 10 min at 4°C. Supernatants were transferred to autosampler vials of the HPLC instrument (Shimadzu, Kyoto Japan). Acetonitrile-isopropyl alcohol (70:30 v/v) was used as a mobile phase at a flow rate of 1 ml/min (Bragagnolo and Rodriguez-Amaya, 2003). Supelcosil LC 18™ DB column (250 × 4.6 mm, 5 μm; Sigma, USA) was used as the HPLC column. Detection was performed by UV at 202 nm and 30°C column oven (Katsanidis and

Addis, 1999). Quantification was carried out by external standardization using Class VP software. The results were expressed as µg/g.

Statistical analysis

The experimental results were reported as means±SD. Statistical analysis was performed using SPSS Software. Analysis of variance (ANOVA) and an LSD test were used to compare the experimental groups with the controls.

RESULTS

In the study, the effects of resveratrol on the levels of the fatty acids and some lipophilic vitamins in the liver of male Winstar rats by induced-fructose were examined. Palmitic acid (16:0), palmitoleic acid (16:1n7), heptadeconoic acid (17:0), stearic acid (18:0), oleic acid 18:1n7, n9) linoleic acid (18:2, n-6), linolenic acid (18:3, n-3) eicosanoic acid (FA20:2 n-6), eicosatrienoic acid (20:3, n-6), arachidonic acid (20:4 n6), eicosapentaenoic acid (20:5, n-3), docosatetraenoic acid, docosapentaenoic acid (22:5 n6) and docosahexaenoic acid (22:6, n-3) were observed in fatty acid components of the liver. Of these, palmitic, stearic, oleic, linoleic and arachidonic acids were present in higher quantities in animals of the control group (Table I).

The fatty acid composition of liver is shown in Table I. The liver palmitic acid level (16:0), linoleic acid(18:2, n-6) and eicosatrienoic acid (20:3, n-6) levels were significantly higher in the F groups than the C group (p < 0.05). Palmitic acid level (16:0), palmitoleic acid (16:1 n7), eicosatrienoic acid (20:3, n-6) and stearic acid (18:0) levels were significantly higher in the R groups than the C group (p < 0.001, p < 0.05).

Oleic acid 18:1n7, n9), linolenic acid (18:3, n-3) docosahexaenoic acid (22:6, n-3) and levels were significantly lower in the F and R groups than the C group (p<0.05, p<0.01, p<0.001). Monosaturated fatty acids (MUFA) levels and n6/n3 ratios were significantly higher in the R groups than the C group (p<0.01, p<0.001). MUFA/ PUFA ratio were significantly lower in F groups than the C group (p<0.01) and ome-3 (n3) levels were significantly lower in the F and R groups than the C group (p<0.001). omega 6 (n6), arachidonic acid (20:4 n6) levels has decreased (p<0.05) and pufa (polyunsaturated fatty acids) levels has meaningless changes statistically (p>0.05).

In the liver tissue, retinol, α-tocopherol levels were decreased in the F groups when compared to C group (p<0.01, p<0.01,). Retinol, levels were decreased, α-tocopherol levels were increased in R groups when compared to C group (p<0.01, p<0.01). Vitamin D$_3$ and cholesterol levels were increased in the F groups when compared to C group (p<0.01, p<0.01). Vitamin D$_3$ levels were increased and cholesterol levels were decreased in the (R) groups when compared to C group (p<0.01, p<0.01).

Table I.- Fatty acıds composıtıon of liver (%).

Yağ asitleri	Control	Fructose	Fructose + Resveratrol
FA16:0	17.49±0.50[a]	18.97±0.41[b]	20.37±0.16[d]
FA16:1n7	1.11±0.14 [a]	1.66±0.12[c]	2.09±0.11 [d]
FA17:0	0.67±0.03 [a]	0.59±0.03 [a]	0.57±0.02 [a]
FA18:0	19.32±0.33 [a]	19.63±0.44[a]	17.60±0.46 [c]
FA18:1 n7	3.20±0.07 [a]	3.20±0.07 [a]	4.34±0.13 [d]
FA18:1 n9	5.45±0.78 [a]	5.80±0.36 [a]	6.34±0.42 [a]
FA18:2 n6	15.13±0.67 [a]	16.78±0.4[b]	17.42±0.43[c]
FA18:3 n3	0.24±0.04	0.11±0.03[b]	0.04±0.04[c]
FA18:3 n6	0.81±0.05	0.61±0.16	0.34±0.13[b]
FA20:2 n6	0.29±0.01	0.26±0.01	0.34±0.02
FA20:3 n6	0.32±0.06	0.64±0.05[b]	0.84±0.11[d]
FA20:4 n6	27.14±0.18	25.09±0.77 [b]	25.08±0.41 [b]
Fa22:5 n6	0.28±0.02	0.25±0.01	0.26±0.04
FA22:6 n3	4.04±0.13	1.94±0.07 [d]	2.5±0.07 [d]
n3	4.58±0.06	2.58±0.11 [d]	2.73±0.11 [d]
n6	43.99±0.017	43.61±0.96	44.63±0.42
mufa	9.77±0.084	10.71±0.29	12.44±0.17 [c]
pufa	48.43±0.83	46.22±0.92	46.64±0.65
n6/n3	9.62±0.2	17.14±1.02 [d]	16.48±0.59 [d]
Mufa/ pufa	5.20±0.04	4.31±0.19 b	3.74±0.06 [c]
FA16:1/ FA16:0	0.06±0.01	0.08±0.03[b]	0.10±0.04[c]
FA18:1 / FA18:0	0.28±0.02	0.29±0.02	0.36±0.04[c]
FA18:3/FA18:2	0.05±0.01	0.03±0.01[b]	0.01±0.0[d]
FA20:4 / FA20:3	84.81±0.83	39.20±0.86[d]	29.85±0.48[d]

a, p > 0.05; b, p < 0.05; c, p < 0.01; d, p < 0.001.

Table II.- Some lipophilic vitamin parameters of liver.

	Control	Fructose	Fructose + Resveratrol
VitaminD$_3$ (µg/g)	3.37±0.19	3.95±0.07[b]	14.37±0.48[d]
Alfa-tocoferoll (µg/g)	16.89±0.26	13.30±0.12[b]	17.23±0.29
Cholesterol (µg/g)	2661.36± 12.08	3430.20± 19.03[d]	3390.53± 13.09[d]
Retinol (µg/g)	443.33± 9.68	409.66± 7.69[b]	354.90± 15.73[d]

a, p > 0.05; b, p < 0.05; c, p < 0.01; d, p < 0.001.

DISCUSSION

Resveratrol (3,5,4′-trihydroxystilbene) is a naturally occurring polyphenol present in grapes, berries, peanuts and other food vegetables. Resveratrol has many remarkable effects in mammals. Supplementation of resveratrol into mice on high fat diets increases mitochondrial content/ activity in liver and improves hepatosteatosis (Baur *et al.*, 2006; Mercader *et al.*, 2011; Lagouge *et al.*, 2006; Ahn *et al.*, 2008). Decreased leptin levels and increased IL 6 and TNF alfa levels were shown in NAFLD, and resveratrol reduced the elevated levels of TNF-α and IL 6 (Kang *et al.*, 2010).

Although chronic inflammation has been implicated in its pathogenesis and severity of nonalcoholic fatty liver, oxidative stress plays an important role in nonalcoholic fatty liver development and progression (Angulo, 2007; Botella-Carretero *et al.*, 2010). Chronic liver diseases are often associated with decreased antioxidant defenses. Different antioxidants exhibit positive effects on liver damage (Harrison *et al.*, 2013; Kugelmas *et al.*, 2003; Thong Ngam *et al.*, 2007).

Resveratrol is the one of the important antioxidant, it has antioxidant properties as an reactive oxygen species scavenger, metal chelators and have rewarding effects on diabetics and obeses. Resveratrol exhibit beneficial biological activities in human health as antiplatelet, anticancer, neuroprotector, cardioprotector, vasoprotective, anti-inflammator and anti-aging (Rhee *et al.*, 2013; Barchetta *et al.*, 2013; Kitson and Roberts, 2012; White and Cooke, 2000; Wu *et al.*, 2013; Wilson *et al.,* 1996; Karlsson *et al.*, 2000; Zern *et al.*, 2003; Jeandet *et al.*, 2012).

Cell proliferation and differentiation is regulated by Vitamin D. Vitamin D possess anti-inflammatory, anti-fibrotic and immunomodulatory properties (Kitson and Roberts, 2012). Vitamin D deficiency may result in insulin resistance, metabolic syndrome and cardiovascular diseases and cancer (Rhee *et al.*, 2013). Vitamin D deficiency and NAFLD is affiliated with inflammation and oxidative stress. Inflammation is the common pathogenic mechanism for the two diseases. And both diseases are related with cardiovascular disease, type 2 diabetes and insulin resistance. Studies has shown that low Vitamin D levels were affiliated with the improvement of NAFLD (Yuan *et al.*, 2006; Yanagitani *et al.*, 2004; Schwedhelm *et al.*, 2003; Ross and Zolfaghari, 2004; Mecradır *et al.*, 2011; Lagouge *et al.*, 2006; Rhee *et al.*, 2013). NAFLD individuals have decreased serum 25(OH)D concentrations that perform a function in the development and improvement of NAFLD (Targher *et al.*, 2007; Eliades *et al.*, 2013; Jablonski *et al.*, 2013).

Barchetta *et al.* (2011) all have shown decreased vitamin D levels are related with the existance of NAFLD separately from metabolic syndrome, diabetes and insulin-resistance profile. High vitamin D level reduce the risk for nonalcholic fatty liver (Rhee *et al.*, 2013). Decreases in DBP titers are seen in patients with advanced liver or kidney disease (McCarthy and Rinella, 2012) and this may help us to understand the little increase in our fructose fatty liver group. But increased vitamin D3 level in fruc+Res group is a conflicting result.

α-tocopherol fulfils as a pyroxyl radical scavenger and chain-breaking antioxidant. It interacts directly with the oxidizing radicals (Burton and Ingold, 1986; Jones *et al.*, 1995) and protect the cells from reactive oxygen species (Cortez-Pinto *et al.*, 2006; Burton and Ingold, 1986). Also polyunsaturated fats and low-density lipoproteins (LDL) in cell membranes protects the cell from oxidation by the α-tocopherol (Botella-Carretero *et al.*, 2010). Decreased antioxidant defenses are often observed with chronic liver diseases. Vitamin E levels have been shown to be decreased in chronic liver diseases which is confirmed with our study and resveratrol increased α-tocopherol levels in our study, but the role of Vitamin E supplementation in clinical conditions is still debated (Patra *et al.*, 2001; Di Sario *et al.*, 2007). The use of Vitamin E, slows the progression of NAFLD to NASH (Yu *et al.*, 2010).

Retinol plays important roles in metabolism. It controls cellular growth and differentiation (Dong *et al.*, 2012; Xiao *et al.*, 2012), it inhibits hepatic cell transformation and helps in the production of proinflammatory cytokines in macrophages (Yang *et al.*, 2011; Botella-Carretero *et al.*, 2010). Retinol is a protective antioxidant. It also suppress proliferation of hepatoma cells, reduce inflammatory reactions and neutralizes reactive oxygen species (Di Sario *et al.*, 2007). Utilization/metabolism of retinol is greatest when liver retinol stores and circulating holo-RBP4 concentrations are high (Cifelli *et al.*, 2008; Alapatt, 2013).

In our result, resveratrol has decreased levels of hepatic retinol. Mercader *et al.* (2011) have shown that resveratrol reduces Retinol-binding protein 4 expression in white adipose tissue. Botella-Carretero *et al.* (2010) and Villaca Chaves *et al.* (2008) have shown relation of nonalcoholic fatty liver with Vitamin A. Also, a study made by Musso *et al.* (2007) has shown pathogenic role of decreased intakes of Vitamin A in nonalcoholic fatty liver. İncreased concentrations of serum retinol lower the risk of hepatocellular carcinoma and transgenic mice with hepatic loss of retinoic acid receptor function which causes liver tumors and steatohepatitis (Botella-Carretero *et al.*, 2010; Yuan *et al.*, 2006; Yanagitani *et al.*, 2004). Pathogenesis of fatty liver is may be associated with Decreased hepatic

retinol levels (Botella-Carretero *et al*., 2010; Schwedhelm *et al*., 2003; Ross and Zolfaghari, 2004).

A study made by Chen *et al*. (2012) has shown that high-fat fed C57BL/6J mice liver cholesterol level is decreased by dietary resveratrol of which confirm our result. Laden and Porter (2001) have shown that resveratrol reduced cholesterol synthesis by inhibiting squalene monooxygenase *in vitro*, a rate-limiting enzyme in cholesterol biosynthesis. Zhu *et al*. (2008) and Do *et al*. (2008) has reported that two doses of dietary resveratrol, 0.02% and 0.06% w/w, inhibit hepatic HMG-CoA reductase, which may reduce the hepatic cholesterol pool and prevent liver from cholesterol accumulation. İncreased synthesis of cholesterol and expression of fatty acid synthase (FAS) is associated with copper deficiency and in intestine Copper uptake protein Ctr1 is depleted by high dietary fructose (Burkhead *et al*., 2013).

Many of the chronic diseases such as, obesity, autoimmune diseases, cardiovascular disease, diabetes, cancer, rheumatoid arthritis, asthma, depression and NAFLD are associated with over production of IL-6, TNF. These factors increase by increases in omega-6 fatty acid intake and decrease by increases in omega-3 fatty acid intake, either ALA or EPA and DHA (Simopoulos, 2004).

In the liver of the obese, NAFLD patients is n-3 long-chain polyunsaturated FA (n-3 LCPUFA), depletion is observed with substantial diminution in eicosapentaenoic acid (20:5, n-3; EPA) and docosahexaenoic acid (22:6, n-3; DHA) levels (Rhee *et al*., 2013; Kitson and Roberts, 2012) which has been related to higher utilization of n-3 LCPUFA due to oxidative stress and defective (White and Cooke, 2000; Pettinelli *et al*., 2013). In our study; n-3 long-chain polyunsaturated FA (n-3 LCPUFA) depletion is observed but not changed by resveratrol inducing.

The desaturating enzymes, Δ9-desaturase [stearoyl-CoA-desaturase (SCD)], Δ6-desaturase (Δ6D) and Δ5-desaturase (Δ5D), introduce *cis*-double bonds in the carbon chain of long chain fatty acids (Nakamura and Nara, 2004). Stearoyl-CoA desaturase is a key enzyme expressed in the liver and is involved in the synthesis of monounsaturated long-chain FAs from saturated fatty acyl-CoAs. It catalyzes palmitoyl and stearoyl-CoA to palmitoleoyl and oleoyl-CoA, respectively (Toshimitsu *et al*., 2007; Ntambi *et al*., 2002).

The ratio of C16:1 to C16:0 or C18:1 to C18:0 is used as D9 desaturation index (Lee *et al*., 1998). Incresed ratio of C16:1 to C16:0 or C18:1 to C18:0 fructose and fructose plus resveratrol group shows increased SCD activity, sign of fat accumulation in present study.

The velocity restriction step in the production of 20:4 and 22:6 is the desaturation of 18:2 (n6) and 18:3 (n3) by D6 and D5 deasaturases (Youdim *et al*., 2002). Both linolenic acid (18: 3 n-3) and linoleic acid (18:2 n-6) are metabolized by longer chain fatty acids, substantially in the liver. 18:3 is converted to eicosapentaenoic acid and hence to docosahexaenoic acid and 18:2 is the metabolic pioneer of arachidonic acid (AA). In the present study (fruc and fruc+res group), arachidonic and docosahexaenoic acids, delta 6 and delta 5 desaturase enzymes products levels are decreased as a result of fat acumilation as sign of decreases in delta 6 and delta 5 desaturase enzymes.

CONCLUSIONS

Acording to our results resveratrol of which is a naturally occuring antioxidant, has diverse effects on fatty acid composition and lipophilic vitamin of fructose induced nonalcholic fatty liver. Further researches are needed on effect of resveratrol on nonalcoholic fatty liver disease.

ACKNOWLEDGMENTS

Statement of conflict of interest
Authors have declared no conflict of interest.

REFERENCES

Ahn, I., Cho, S., Kim, S., Kwon, D. and Ha, T., 2008. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. *J. Hepatol.,* **49**: 1019–1028. https://doi.org/10.1016/j.jhep.2008.08.012

Alapatt, P., Guo, F., Komanetsky, S.M., Wang, S., Ca,i J., Sargsyan, A., Rodríguez Díaz, E., Bacon, B.T., Aryal, P. and Graham, T.E., 2013. Liver retinol transporter and receptor for serum retinol-binding protein (RBP4). *J. biol. Chem*., **288**: 1250-1265. https://doi.org/10.1074/jbc.M112.369132

Angulo, P., 2007. Obesity and nonalcoholic fatty liver disease. *Nutr. Rev*., **65**: 57–63. https://doi.org/10.1111/j.1753-4887.2007.tb00329.x

Barchetta, I., Angelico, F., Del Ben, M., Baroni, M.G., Pozzilli, P., Morini, S. and Cavallo, M.G., 2011. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. *BMC Med*., **9**: 85. https://doi.

org/10.1186/1741-7015-9-85

Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis. K., Pistell, P.J., Poosala, S., Becker, K.G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K.W., Spencer, R.G., Lakatta, E.G., Le Couteur, D., Shaw, R.J., Navas, P., Puigserver, P., Ingram, D.K., de Cabo, R. and Sinclair, D.A., 2006. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature*, **444**: 337–342. https://doi.org/10.1038/nature05354

Bernal, C., Martin-Pozuelo, G., Lozano, A.B., Sevilla, A., Garcia-Alonso, J., Canovas, M. and Periago, M.J., 2013. Lipid biomarkers and metabolic effects of lycopene from tomato juice on liver of rats with induced hepatic steatosis. *J. Nutr. Biochem.*, **24**: 1870–1881. https://doi.org/10.1016/j.jnutbio.2013.05.003

Botella-Carretero, J.I., Balsa J.A., Vázquez, C., Peromingo, R., Díaz-Enriquez, M. and Escobar-Morreale, H.F., 2010. Retinol and alpha-tocopherol in morbid obesity and nonalcoholic fatty liver disease. *Obestet. Surg.*, **20**: 69-76. https://doi.org/10.1007/s11695-008-9686-5

Bragagnolo, N. and Rodriguez-Amaya, D.B., 2003. Comparison of the cholesterol content of Brazilian chicken and quail eggs. *J. Fd. Compos. Analy.*, **16**: 147–153. https://doi.org/10.1016/S0889-1575(02)00129-1

Browning, J.D. and Horton J.D., 2004. Molecular mediators of hepatic steatosis and liver injury. *J. clin. Invest.*, **114**: 147–152. https://doi.org/10.1172/JCI200422422

Burkhead, J.L. and Lutsenko S., 2013. The role of copper as a modifier of lipid metabolism. In: *Lipid metabolism* (ed. R.V. Baez). InTech Publisers, Janeza Trdine 9, 51000 Rijeka, Croatia. https://doi.org/10.5772/51819

Burton, G.W. and Ingold, K.U., 1986. Vitamin E: application of principles of physical organic chemistry to the exploration of its structure and function. *Accounts Chem. Res.*, **19**: 194–201. https://doi.org/10.1021/ar00127a001

Chen, Q., Wang, E., Ma, L. and Zhai, P., 2012. Dietary resveratrol increases the expression of hepatic 7α-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice. *Lipids Hlth. Dis.*,**11**: 56. https://doi.org/10.1186/1476-511X-11-56

Christie, W.W., 1992. *Gas chromatography and lipids*. The Oil Press, Glasgow, pp. 302.

Cifelli, C. J., Green, J. B., Wang, Z., Yin, S., Russell,

R. M., Tang, G. and Green, M.H., 2008. Kinetic analysis shows that vitamin A disposal rate in humans is positively correlated with vitamin A stores. *J. Nutr.*, **138**: 971–977.

Cortez-Pinto, H., Jesus, L., Barros, H., Lopes, C., Moura, M.C. and Camilo, M.E., 2006. How different is the dietary pattern in non-alcoholic steatohepatitis patients? *Clin. Nutr.*, **25**: 816–823. https://doi.org/10.1016/j.clnu.2006.01.027

Di Sario, A., Candelaresi, C., Omenetti, A. and Benedetti, A., 2007. Vitamin E in chronic liver diseases and liver fibrosis. *Vitam. Horm.*, **76**: 551-573. https://doi.org/10.1016/S0083-6729(07)76021-1

Do, G.M., Kwon, E.Y., Kim, H.J., Jeon, S.M., Ha, T.Y., Park, T. and Choi, M.S., 2008. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. *Biochem. biophys. Res. Commun.*, **374**: 55-59. https://doi.org/10.1016/j.bbrc.2008.06.113

Dong, H., Lu, F.E. and Zhao, L., 2012. Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. *Chin. J. Integr. Med.*, **18**: 152-160. https://doi.org/10.1007/s11655-012-0993-2

Eliades, M., Spyrou, E., Agrawal, N., Lazo, M., Brancati, F.L., Potter, J.J., Koteish, A.A., Clark, J.M., Guallar, E. and Hernaez, R., 2013. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. *Aliment. Pharmacol. Ther.*, **38**: 246-254. https://doi.org/10.1111/apt.12377

Elizabeth, L.Y., Jeffrey, B.S. and Joel, E.L., 2010. Non-alcoholic fatty liver disease: epidemiology, pathophysiology, diagnosis and treatment. *Paediat. Child Hlth.*, **20**: 26–29.

Gomez-Zorita, S., Fernandez-Quintela, A., Macarulla, M.T., Aguirre, L., Hijona, E., Bujanda, L., Milagro, F., Martinez, J.A. and Portillo, M.P., 2012. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. *Br. J. Nutr.*, **107**: 202-210. https://doi.org/10.1017/S0007114511002753

Hara, A. and Radin, N.S., 1978, Lipid extraction of tissues with a low-toxicity solvent. *Analyt. Biochem.*, **90**: 420-426. https://doi.org/10.1016/0003-2697(78)90046-5

Harrison, S.A., Torgerson, S., Hayashi, P., Ward, J. and Schenker, S., 2003. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. *Am. J. Gastroenterol.*, **98**: 248. https://doi.org/10.1111/j.1572-0241.2003.08699.x

Jablonski, K.L., Jovanovich, A., Holmen, J., Targher, G.,

McFann, K., Kendrick, J. and Chonchol, M., 2013. Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. *Nutr. Metab. Cardiovasc. Dis.,* **23**: 792-798. https://doi.org/10.1016/j.numecd.2012.12.006

Jeandet, P., Delaunois, B., Aziz, A., Donnez, D., Vasserot, Y., Cordelier, S. and Courot, E., 2012. Metabolic engineering of yeast and plants for the production of the biologically active hydroxystilbene, resveratrol. *J. Biomed. Biotechnol.*, **2012**: Article ID 579089. https://doi.org/10.1155/2012/579089

Jones, D.P., Kagan, V.E., Aust, S.D., Reed, D.J. and Omaye, S.T., 1995. Impact of nutrients on cellular lipid peroxidation and antioxidant defense system. *Fundam. appl. Toxicol.*, **26** :1–7. https://doi.org/10.1006/faat.1995.1069

Kang, J.S., Lee, W.K., Yoon, W.K., Kim, N., Park, S.K., Park, H.K., Ly, S.Y., Han, S.B., Yun, J., Lee, C.W., Lee, K., Lee, K.H., Park, S.K. and Kim, H.M., 2011. A combination of grape extract, green tea extract and L-carnitine improves high-fat diet induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice. *Phytother. Res.*, **25**: 1789-1795. https://doi.org/10.1002/ptr.3476

Kang, L., Heng, W., Yuan, A., Baolin, L. and Fang, H., 2010. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: Relative to inhibition of inflammatory responses. *Biochimie*, **92**: 789–799. https://doi.org/10.1016/j.biochi.2010.02.024

Karlsson, J., Emgard, M., Brundin, P. and Burkitt, M.J., 2000. Trans-resveratrol protects embryonic mesencephalic cells from tert-butyl hydroperoxide: electron paramagnetic resonance spin trapping evidence for a radical scavenging mechanism. *J. Neurochem.*, **75**: 141–150. https://doi.org/10.1046/j.1471-4159.2000.0750141.x

Katsanidis, E. and Addis, P.B., 1999. Novel HPLC analysis of tocopherols, and cholesterol in tissue. *Free Rad. Biol. Med.*, **27**: 1137–1140. https://doi.org/10.1016/S0891-5849(99)00205-1

Kim, S., Jin, Y., Choi, Y. and Park, T., 2011. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. *Biochem. Pharmacol.*, **81**: 1343–1351. https://doi.org/10.1016/j.bcp.2011.03.012

Kitson, M.T. and Roberts, S.K., 2012. D-livering the message: the importance of vitamin D status in chronic liver disease. *J. Hepatol.*, **57**: 897-909. https://doi.org/10.1016/j.jhep.2012.04.033

Kugelmas, M., Hill, D.B., Vivian, B., Marsano, L. and McClain, C.J., 2003. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. *Hepatology*, **38**: 413–419. https://doi.org/10.1053/jhep.2003.50316

Laden, B.P. and Porter, T.D., 2001. Resveratrol inhibits human squalene monooxygenase. *Nutr. Res.*, **21**: 747-753. https://doi.org/10.1016/S0271-5317(01)00287-1

Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P. and Auwerx, J., 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. *Cell*, **127**: 1109–1122. https://doi.org/10.1016/j.cell.2006.11.013

Lee, K.N., Pariza, M.W., Ntambi, J.M., 1998. Conjugated linoleic acid decreases hepatic stearoyl-CoA desaturase mRNA expression. *Biochem. biophys. Res. Commun.*, **248**: 817–821. https://doi.org/10.1006/bbrc.1998.8994

López-Cervantes, J., Sánchez-Machado, D.I. and Ríos-Vázquez, N.J., 2006. High performance liquid chromatography method for the simultaneous quantification of retinol, tocopherol and cholesterol in shrimp waste hydrolysate. *J. Chromatogr. A*, **1105**: 135–139. https://doi.org/10.1016/j.chroma.2005.08.010

Mao, Z.M., Song, H.Y., Yang, L.L., Liu, T., Li, D.F., Zheng, P.Y., Liu, P. and Ji, G., 2012. Effects of the mixture of *Swertia pseudochinensis* Hara and *Silybum marianum* Gaertn extracts on CCl(4)-induced liver injury in rats with non alcoholic fatty liver disease. *Medline*, **10**: 193-199.

Masterjohn, C. and Bruno, R.S., 2012. Therapeutic potential of green tea in nonalcoholic fatty liver disease. *Nut. Rev.*, **70**: 41-56. https://doi.org/10.1111/j.1753-4887.2011.00440.x

McCarthy, E.M. and Rinella, M.E., 2012. The role of diet and nutrient composition in nonalcoholic fatty liver disease. *J. Acad. Nutr. Dietet.*, **112**: 401–409. https://doi.org/10.1016/j.jada.2011.10.007

Mercader, J., Palou, A. and Bonet, M.L., 2011. Resveratrol enhances fatty acid oxidation capacity and reduces resistin and retinol-binding protein 4 expression in white adipocytes. *J. Nutr. Biochem.*, **22**: 828–834. https://doi.org/10.1016/j.jnutbio.2010.07.007

Musso, G., Gambino, R., De Michieli, F., Biroli, G., Premoli, A., Pagano, G., Bo, S., Durazzo, M. and Cassader, M., 2007. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin

resistance and metabolic syndrome: possible role of vitamin A intake. *Am. J. clin. Nutr*., **86**: 661–671.

Nakamura, M.T. and Nara, T.Y., 2004. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. *Annu. Rev. Nutr*., **24**: 345-376. https://doi.org/10.1146/annurev. nutr.24.121803.063211

Ntambi, J.M., Miyazaki, M., Stoehr, J.P., Lan, H., Kendziorski, C.M., Yandell, B.S., Song, Y. Cohen, P., Friedman, J.M. and Attie, A.D., 2002. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. *Proc. natl. Acad. Sci. U.S.A.,* **99**: 11482-11486. https://doi.org/10.1073/ pnas.132384699

Oliveira C.P., L.C. da Costa Gayotto, C., Tatai, B.I., Della Bina, M., Janiszewski, E.S., Lima, D.S., Abdalla, F.P., Lopasso, F.R., Laurindo, A.A. and Laudanna, A.A., 2002. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. *J. cell. mol. Med*., **6**: 399–406. https://doi.org/10.1111/j.1582-4934.2002. tb00518.x

Parker, H.M., Johnson, N.A., Burdon C.A., Cohn S.J., O'Connor, H.T. and George, J., 2012. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J. Hepatol*., **56**: 944–951. https://doi.org/10.1016/j. jhep.2011.08.018

Patra, R.C., Swarup, D. and Dwivedi, S.K., 2001. Antioxidant effects of α tocopherol, ascorbic acid and L-methionine on lead induced oxidative stress to the liver, kidney and brain in rats. *Toxicology*, **162**: 81–88. https://doi.org/10.1016/S0300-483X(01)00345-6

Petta, S., Muratore, C. and Craxì A., 2009. Non-alcoholic fatty liver disease pathogenesis: The present and the future. *Digest. Liver Dis*., **41**: 615–625. https:// doi.org/10.1016/j.dld.2009.01.004

Pettinelli, P., del Pozob, T., Arayac, J., Rodrigoa, R., Arayad, A.V., Smoke, G., Csendesf, A., Gutierrezf, L., Rojasf, J., Kornf, O., Maluendaf, F., Diazf, J.C., Rencoretf, G., Braghettof, I., Castillof, J., Poniachikg, J. and Videla, L.A., 2009. Enhancement in liver SREBP-1c/PPAR-α ratio and steatosis in obese patients: Correlations with insulin resistance and n-3 long-chain polyunsaturated. fatty acid depletion. *Biochim. biophys. Acta*, **1792**: 1080–1086. https://doi.org/10.1016/j.bbadis.2009.08.015

Rhee, E.J., Kim, M.K., Park, S.E. Park, C.Y., Baek, K.H., Lee, W.Y., Kang, M.I., Park, S.W., Kim, S.W. and Oh, KW., 2013. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease

in healthy men independent of metabolic syndrome. *Endocr. J.,* **60**: 743-752. https://doi.org/10.1507/ endocrj.EJ12-0387

Ross, A.C. and Zolfaghari, R., 2004. Regulation of hepatic retinol metabolism:perspectives from studies on vitamin A status. *J. Nutr*., **134**: 269–275.

Schwedhelm, E., Maas, R., Troost, R. and Böger, R.H., 2003. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. *Clin. Pharmacokinet*., **42**: 437–459. https://doi. org/10.2165/00003088-200342050-00003

Serviddio, G., Bellanti, F. and Vendemiale, G., 2013. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. *Free Rad. Biol. Med*., **65**: 952–968. https://doi.org/10.1016/j. freeradbiomed.2013.08.174

Shang, J., Chen L.L., Xiao, F.X., Sun, H., Ding, H.C. and Xiao, H., 2008. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. *Acta Pharmacol. Sin*., **29**: 698-706. https://doi.org/10.1111/j.1745-7254.2008.00807.x

Simopoulos, A.P., 2004. Omega-6/Omega-3 essential fatty acid ratio and chronic diseases. *Fd. Rev. Int*., **20**: 77–90. https://doi.org/10.1081/FRI-120028831

Targher, G., Bertolini, L., Scala, L., Cigolini, M., Zenari, L. and Fralezza, G., 2007. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. *Nutr. Metab. Cardiovasc. Dis*., **17**: 517–524. https://doi.org/10.1016/j. numecd.2006.04.002

Tessari, P., Coracina, A., Cosma, A. and Tiengo, A., 2009. Hepatic lipid metabolism and non-alcoholic fatty liver disease. *Nutr. Metab. Cardiovasc. Dis.,* **4**: 291-302. https://doi.org/10.1016/j.numecd.2008.12.015

Thong Ngam, D., Samuhasaneeto, S., Kulaputana, O. and Klaikeaw, N., 2007. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. *World J. Gastroenterol*., **13**: 5127-5132. https://doi. org/10.3748/wjg.v13.i38.5127

Toshimitsu, K., Matsuura, B., Ohkubo, I., Niiya, T., Furukawa, S., Hiasa, Y, Kawamura, M., Ebihara, K. and Onji, M., 2007. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. *Nutrition*, **23**: 46-52. https://doi.org/10.1016/j. nut.2006.09.004

Villaca Chaves, G., Pereira, S.E., Saboya, C.J. and Ramalho, A., 2008. Non-alcoholic fatty liver disease and its relationship with the nutritional status of vitamin A in individuals with class III obesity. *Obestet. Surg*., **18**: 378–385. https://doi.

org/10.1007/s11695-007-9361-2

White, P. and Cooke, N., 2000. The multifunctional properties and characteristics of vitamin D-binding protein. *Trends Endocrinol. Metab.*, **11**: 8. https://doi.org/10.1016/S1043-2760(00)00317-9

Wilson, T., Knight, T.J., Beitz, D.C., Lewis, D.S. and Engen, R.L., 1996. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. *Life Sci.*, **59**: 15–21. https://doi.org/10.1016/0024-3205(96)00260-3

Wu, C.F., Yang, J.Y. Wang, F. and Wang, X.X., 2013. Resveratrol: Botanical origin, pharmacological activity and applications. *Chinese J. Nat. Med.*, **11**: 1–15. https://doi.org/10.3724/SP.J.1009.2013.00001

Xiao, J., Ching, Y.P., Liong, E.C., Nanji, A.A., Fung, M.L. and Tipoe, G.L., 2013. Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model. *Eur. J. Nutr.*, **52**: 179-191. https://doi.org/10.1007/s00394-012-0301-0

Xiao, J., Liong, E.C., Ching, Y.P., Chang, R.C., So, K.F., Fung, M.L. and Tipoe, G.L., 2012. Lycium barbarum polysaccharides protect mice liver from carbon tetrachloride-induced oxidative stress and necroinflammation. *J. Ethnopharmacol.*, **139**: 462-470. https://doi.org/10.1016/j.jep.2011.11.033

Xin, P., Han, H., Gao, D., Cui, W., Yang, X., Ying, C., Sun, X. and Hao, L., 2013. Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats. *Fd. Chem. Toxicol.*, **52**: 12-18. https://doi.org/10.1016/j.fct.2012.10.026

Yanagitani, A., Yamada, S., Yasui, S., Shimomura, T., Murai, R., Murawaki, Y., Hashiguchi, K., Kanbe, T., Saeki, T., Ichiba, M., Tanabe, Y., Yoshida, Y., Morino, S., Kurimasa, A., Usuda, N., Yamazaki, H., Kunisada, T., Ito, H., Murawaki, Y. and Shiota, G., 2004. Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. *Hepatology*, **40**: 366–375. https://doi.org/10.1002/hep.20335

Yang, L.L., Wang, M., Liu, T., Song, H.Y., Li, D.F., Zheng, P.Y., Liu, P. and Ji, G., 2011. Effects of Chinese herbal medicine Jiangzhi Granule on expressions of liver X receptor α and sterol regulatory element-binding protein-1c in a rat model of non-alcoholic fatty liver disease. *J. Chinese Integr. Med.,* **9**: 998-1004. https://doi.org/10.3736/jcim20110911

Youdim, K.A., Martin, A. and Joseph, J.A., 2000. Essential fatty acids and the brain: possible health implications. *Int. J. Dev. Neurosci.*, **18**: 383-399. https://doi.org/10.1016/S0736-5748(00)00013-7

Yu, E.L., Schwimmer, J.B. and Lavine, J.E., 2010. Non-alcoholic fatty liver disease: epidemiology, pathophysiology, diagnosis and treatment. *Paediatr. Child Health*, **20**: 26–29.

Yuan, J.M., Gao, Y.T., Ong, C.N., Ross, R.K. and Yu, M.C., 2006. Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. *J. Natl. Cancer Inst.*, **98**: 482–490. https://doi.org/10.1093/jnci/djj104

Zern, T.L., West, K.L. and Fernandez, M.L., 2003. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. *J. Nutr.*, **133**: 2268–2272.

Zhu, F.S., Liu, S., Chen, X.M., Huang, Z.G. and Zhang, D.W., 2008. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. *World J. Gastroenterol.*, **14**: 6395–6400. https://doi.org/10.3748/wjg.14.6395

Zivkovic, A.M., German, J.B. and Sanyal, A.J., 2007. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. *Am. J. clin. Nutr.*, **86**: 285–300.